Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Change in Account Payables (2018 - 2025)

Arcturus Therapeutics Holdings' Change in Account Payables history spans 8 years, with the latest figure at -$1.3 million for Q4 2025.

  • For Q4 2025, Change in Account Payables rose 54.27% year-over-year to -$1.3 million; the TTM value through Dec 2025 reached -$3.0 million, down 254.52%, while the annual FY2025 figure was -$3.0 million, 254.52% down from the prior year.
  • Change in Account Payables reached -$1.3 million in Q4 2025 per ARCT's latest filing, up from -$5.0 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $11.8 million in Q1 2023 to a low of -$12.7 million in Q4 2023.
  • Average Change in Account Payables over 5 years is -$358150.0, with a median of -$1.2 million recorded in 2025.
  • Peak YoY movement for Change in Account Payables: plummeted 569.28% in 2022, then soared 26890.91% in 2023.
  • A 5-year view of Change in Account Payables shows it stood at $1.8 million in 2021, then tumbled by 569.28% to -$8.4 million in 2022, then crashed by 50.76% to -$12.7 million in 2023, then soared by 76.94% to -$2.9 million in 2024, then soared by 54.27% to -$1.3 million in 2025.
  • Per Business Quant, the three most recent readings for ARCT's Change in Account Payables are -$1.3 million (Q4 2025), -$5.0 million (Q3 2025), and $4.4 million (Q2 2025).